Market Intelligence, Clinical Progress, and High-Purity Reagents for Hepatic Targeting, Cardiovascular Disease, and Metabolic Diseases.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ASGR1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ASGR1 ECD-Fc Fusion Protein / Mutant Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). Ca²⁺-dependent folding for lectin activity. |
View ASGR1 Products |
| Gene Delivery | ASGR1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. High titer (>10^8 TU/mL) for hepatocyte engineering and internalization assays. |
View ASGR1 Products |
| Benchmark Ab | Anti-ASGR1 Recombinant Antibody (Positive Control) Sequence-verified positive control for binding and specificity assays (internalization, SPR). |
View ASGR1 Products |
| Validator | ASGR1 siRNA Set Validated knockdown for specificity verification and assay baseline establishment in hepatocyte models. |
View ASGR1 Products |
| Related Target: ASGR2 | ASGR2 (ASGPR H2) Hetero-oligomeric partner subunit; critical for complex formation and ligand specificity. Essential for counter-screening. |
View ASGR2 Products |
| Related Target: LDLR | LDLR Downstream cholesterol clearance pathway; synergistic target for combination therapy and functional validation of ASGR1 inhibition. |
View LDLR Products |
| Related Target: PCSK9 | PCSK9 Synergistic pathway for lipid metabolism and cardiovascular disease; key for combination therapy studies. |
View PCSK9 Products |
| Related Target: TFRC | TFRC (Transferrin Receptor) Alternative intracellular delivery and receptor-mediated endocytosis pathway target; often studied in parallel with ASGR1 for delivery platforms. |
View TFRC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GalNAc/Ligand Binding Kinetics (SPR/BLI) | HEK293 Expressed ECD-Fc fusions with native glycosylation and Ca²⁺-dependent folding, >95% purity, verified by mass spec. |
| ASGR1 vs. ASGR2 Selectivity | Human ASGR1 and ASGR2 ortholog proteins available with >95% purity; mass spec verified for strict counter-screening. |
| Cross-species Cyno/Mouse Evaluation | Human, Cynomolgus, and Mouse ASGR1 ECD-Fc proteins available with identical rigorous QC for translational PK/PD bridging. |
| Internalization & Trafficking (ADC/LYTAC) | High-purity ECD-Fc for SPR; full-length lentivirus particles for rapid stable cell line construction enabling pHrodo/flow cytometry internalization assays. |
| Lack of Standardization / Specific Controls | Clinical Benchmark Antibodies and validated siRNA included for precise assay calibration and knockdown confirmation. |
Live ASGR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ASGR1 therapeutics is accelerating from human genetic validation toward first-in-class modalities. Large-scale genetic studies (e.g., Regeneron) have demonstrated that loss-of-function ASGR1 variants confer lower LDL cholesterol and reduced cardiovascular risk, providing robust genetic rationale. Two major fronts are emerging: (1) targeted hepatic delivery via GalNAc conjugates (siRNA/ASO) leveraging ASGR1 as a portal, dominated by Alnylam, Arrowhead, and Novartis; (2) direct receptor antagonism for cardiovascular disease (CVD) through small molecules and monoclonal antibodies, pursued by Amgen, Novo Nordisk, and Ionis. As first-generation GalNAc-siRNA therapies achieve commercial success, the next wave of R&D is heavily focused on liver-directed ADCs, PROTACs, precision bispecifics, and combination regimens with PCSK9/ANGPTL3 inhibitors. Simultaneously, novel approaches targeting ASGR1-mediated internalization for payload delivery (e.g., LYTAC, antibody-drug conjugates) are advancing through preclinical and early clinical pipelines.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| GalNAc-siRNA / RNAi | Arrowhead, Alnylam, Silence Therapeutics, Novartis | Hypercholesterolemia, ASCVD, ATTR Amyloidosis | Hepatocyte Uptake & KD Validation (Need ASGR1-specific siRNA controls, stable cell lines via lentivirus) |
| Small Molecule Inhibitors | Amgen, Novartis | Cardiovascular Disease, NASH, Metabolic Syndrome | Selectivity Screening (Need WT & Mutant ASGR1 proteins with Ca²⁺ binding site integrity) |
| Monoclonal Antibody / ADC | Novo Nordisk, Ionis, Emerging Biotechs | Severe Dyslipidemia, Hepatocellular Carcinoma (HCC) | Internalization Assay (Need high-purity ECD-Fc for SPR, full-length lentivirus for pHrodo trafficking) |
| Bispecific / Combination | Large Pharma (Exploratory), Various | Refractory CVD, Liver-targeted immunomodulation | Heterodimer Validation (Need ASGR1/ASGR2 cross-reactive panels, ortholog proteins) |
Internal Strategy: Molecular Differentiation & Assay Blueprint
To win in the ASGR1 space, molecules must differentiate along four key dimensions:
- Affinity & pH-Dependent Release: Delivery molecules (GalNAc/ADC) require strong binding at pH 7.4 but rapid dissociation at pH 5.0–6.0 in endosomes. Recommended assay: pH-dependent SPR/BLI using HEK293-expressed ECD-Fc (native glycosylation).
- Internalization Efficiency: Critical for ADC/LYTAC. Use flow cytometry-based internalization (pHrodo) and confocal microscopy with full-length ASGR1 lentivirus stable cell lines.
- Subunit Specificity: Differentiate antibodies targeting ASGR1 monomers vs. ASGR1/ASGR2 hetero-oligomers. Use ASGR1 + ASGR2 dual detection proteins for epitope mapping.
- Cross-Species Reactivity: Ensure comparable affinity across human/cyno/mouse to avoid on-target off-tumor toxicity. Use ortholog protein panel (Human, Cyno, Mouse ASGR1 ECD-Fc).
TarMart provides all essential tools: high-purity (>95%) ECD-Fc proteins (HEK293, native glycans), lentivirus particles, validated siRNAs, and benchmark antibodies – enabling robust assay development from binding kinetics to cell-based functional studies.